Study summary
A reversible BTK pill worked even after older BTK inhibitors
55.6%response rate
What was tested
Pirtobrutinib, a non-covalent BTK inhibitor that works against some resistance mutations, for heavily treated relapsed or refractory marginal zone lymphoma.
What they found
- Response rate was 55.6%, and 53.8% in people who had already taken a covalent BTK inhibitor.
- Median progression-free survival was 16.6 months.
- Only 11.1% stopped because of side effects.
What it means
Offers an option after ibrutinib or zanubrutinib stops working.
Last reviewed 2026-11-15 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.